The role and mechanism of autophagy in sorafenib targeted cancer therapy

Publication date: April 2016
Source:Critical Reviews in Oncology/Hematology, Volume 100
Author(s): Yi Heqing, Long Bin, Ye Xuemei, Li Linfa
Targeting kinase inhibitors (TKIs) are effective tools for treating advanced cancer. However, acquired resistance represents a roadblock in the use of TKIs, such as sorafenib, for cancer therapy. Understanding the acquisition of resistance to sorafenib will help doctors to cope with acquired resistance to TKIs in general and to develop personalized medicine strategies for cancer patients. Autophagy is a biological process that occurs in normal organisms. However, it is also a component of multiple disease processes, including cancer development and progression. However, the roles of autophagy in cancer and in response to cancer therapy are controversial. In this review, we summarize the progress in autophagy and sorafenib resistance research, which is representative of acquired resistance to targeted cancer therapy.



from Cancer via ola Kala on Inoreader http://ift.tt/1XpL8HL
via IFTTT